Galmed Pharmaceuticals Ltd. EBITDA 2011-2026 | GLMD

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA Galmed Pharmaceuticals Ltd.

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	-	42 K	-30.2 M	-22.3 M	-10.3 M	-12.1 M	-16.7 M	10.7 M	9.11 M	-14.6 M	-3.13 M	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
10.7 M	-30.2 M	-8.95 M

Quarterly EBITDA Galmed Pharmaceuticals Ltd.

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-	-	-	-	-	-5.82 M	-	-	-	-4.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
-4.7 M	-5.82 M	-5.26 M

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Biotechnology industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-508 M	-	2.43 %	$ 254 M	Germany
Aligos Therapeutics ALGS	-87.1 M	$ 8.48	6.0 %	$ 83.8 M	USA
Alterity Therapeutics Limited ATHE	-17.3 M	$ 3.66	-1.48 %	$ 8.81 B	Australia
I-Mab IMAB	13.8 M	-	-	$ 866 M	China
AlloVir ALVR	-46.1 M	-	4.14 %	$ 49.1 M	USA
Applied Molecular Transport AMTI	-124 M	-	-	$ 10.1 M	USA
Alexion Pharmaceuticals, Inc. ALXN	3.11 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	31.8 M	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	-26.8 M	-	-13.47 %	$ 169 M	France
Esperion Therapeutics ESPR	60.4 M	$ 2.19	0.92 %	$ 455 M	USA
Evogene Ltd. EVGN	-31 M	$ 0.78	-4.39 %	$ 27.9 M	Israel
Applied Therapeutics APLT	-64.5 M	-	-	$ 8.42 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	-8.18 M	-	-1.52 %	$ 24.7 M	USA
Midatech Pharma plc MTP	-7 M	-	-18.52 %	$ 27.3 M	Britain
Genmab A/S GMAB	6.57 B	$ 28.2	-0.18 %	$ 18 B	Danmark
Grifols, S.A. GRFS	595 M	$ 8.38	2.01 %	$ 6.83 B	Spain
GT Biopharma GTBP	-12.4 M	$ 0.38	2.47 %	$ 2.1 M	USA
Amphastar Pharmaceuticals AMPH	172 M	$ 21.28	4.44 %	$ 995 M	USA
Halozyme Therapeutics HALO	480 M	$ 66.92	-1.33 %	$ 8.02 B	USA
Acorda Therapeutics ACOR	-233 M	-	-24.86 %	$ 820 K	USA
Институт стволовых клеток человека ISKJ	220 M	-	-	-	Russia
Adverum Biotechnologies ADVM	-136 M	-	-	$ 86.2 M	USA
Harmony Biosciences Holdings HRMY	232 M	$ 29.05	0.55 %	$ 1.67 B	USA
Advaxis ADXS	-35.9 M	-	-9.65 %	$ 45.9 M	USA
Aeterna Zentaris AEZS	-8.67 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	-23.9 M	-	-10.17 %	$ 12.2 K	USA
Immatics N.V. IMTX	-86.3 M	$ 10.87	4.17 %	$ 684 M	Germany
Incyte Corporation INCY	1.61 B	$ 95.33	-0.77 %	$ 18.6 B	USA
Aeglea BioTherapeutics AGLE	-242 M	-	-	$ 1.01 B	USA
Akebia Therapeutics AKBA	24.8 M	$ 1.46	4.29 %	$ 375 M	USA
Applied Genetic Technologies Corporation AGTC	-16.2 M	-	-	$ 26.5 M	USA
Allakos ALLK	-190 M	-	-	$ 28.6 M	USA
Can-Fite BioPharma Ltd. CANF	-9.93 M	$ 2.99	2.4 %	$ 4.92 M	Israel
Aptinyx APTX	-62.4 M	-	-39.0 %	$ 4.57 M	USA
Aquestive Therapeutics AQST	-70.5 M	$ 4.2	2.82 %	$ 449 M	USA
Aravive ARAV	-70 M	-	-13.39 %	$ 1.45 M	USA
Arcutis Biotherapeutics ARQT	-11.5 M	$ 24.24	0.1 %	$ 3.08 B	USA
Innate Pharma S.A. IPHA	-47.8 M	$ 1.47	4.26 %	$ 235 M	France
AIkido Pharma AIKI	-55.6 M	-	1.93 %	$ 17.4 M	USA
Celldex Therapeutics CLDX	-284 M	$ 32.59	1.09 %	$ 2.16 B	USA
Autolus Therapeutics plc AUTL	-262 M	$ 1.48	-0.67 %	$ 394 M	Britain
Aptose Biosciences APTO	22 K	-	-45.71 %	$ 1.2 M	Canada
Cidara Therapeutics CDTX	-176 M	-	-	$ 1.41 B	USA
AVROBIO AVRO	10.8 M	-	1083.1 %	$ 745 M	USA
Ayala Pharmaceuticals AYLA	-37.3 M	-	-	$ 7.46 M	Israel
AstraZeneca PLC AZN	1.06 B	-	-	$ 96.9 B	Britain
Akero Therapeutics AKRO	-285 M	-	-	$ 3.67 B	USA
CureVac N.V. CVAC	-412 M	-	-	$ 867 M	Germany
Brainstorm Cell Therapeutics BCLI	-9.75 M	-	-2.5 %	$ 5.88 M	USA
BeiGene, Ltd. BGNE	589 M	-	0.49 %	$ 251 B	Cayman-islands